دوره 12، شماره 1 - ( 11-1402 )
جلد 12 شماره 1 صفحات 48-39 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tamizifar B, Kassaian N, khorasani M R, Sabzali S, Shahzamani K, Adibi P. Evaluating COVID-19 Vaccine Side Effects in Patients With Inflammatory Bowel Disease: A Case-control Study in Iran. Res Mol Med (RMM) 2024; 12 (1) :39-48
URL: http://rmm.mazums.ac.ir/article-1-575-fa.html
URL: http://rmm.mazums.ac.ir/article-1-575-fa.html
Evaluating COVID-19 Vaccine Side Effects in Patients With Inflammatory Bowel Disease: A Case-control Study in Iran. Research in Molecular Medicine. 1402; 12 (1) :39-48
چکیده: (1036 مشاهده)
Background: The COVID-19 pandemic has presented unique challenges for individuals with inflammatory bowel disease (IBD), a group already at increased risk due to altered immune function and immunosuppressive treatments. While vaccines remain the most effective tool for controlling the pandemic, concerns about their safety and potential to worsen IBD symptoms have led to hesitancy among patients. This study explored the side effects of COVID-19 vaccines in IBD patients compared to healthy individuals.
Materials and Methods: This case-control study was conducted in Isfahan, Iran, from September to December 2021. The study involved 86 IBD patients and 91 healthy participants who had received at least one dose of a COVID-19 vaccine. Information about vaccine-related side effects was gathered through interviews, and statistical methods were used to identify any significant differences between the two groups.
Results: The findings showed that vaccine side effects were mild and temporary in both groups, with no significant differences in overall frequency (70% in IBD patients vs 67% in healthy controls). Common side effects included localized pain, fatigue, headaches, and fever, all of which resolved quickly. Notably, no IBD patients reported a flare of their condition after vaccination. Despite this, fewer IBD patients opted for second or third doses, likely due to lingering concerns about adverse effects.
Conclusion: COVID-19 vaccination is safe for IBD patients, with side effects similar to or less frequent than those seen in the general population. Clear communication and targeted strategies are needed to alleviate vaccine hesitancy in this vulnerable group.
Materials and Methods: This case-control study was conducted in Isfahan, Iran, from September to December 2021. The study involved 86 IBD patients and 91 healthy participants who had received at least one dose of a COVID-19 vaccine. Information about vaccine-related side effects was gathered through interviews, and statistical methods were used to identify any significant differences between the two groups.
Results: The findings showed that vaccine side effects were mild and temporary in both groups, with no significant differences in overall frequency (70% in IBD patients vs 67% in healthy controls). Common side effects included localized pain, fatigue, headaches, and fever, all of which resolved quickly. Notably, no IBD patients reported a flare of their condition after vaccination. Despite this, fewer IBD patients opted for second or third doses, likely due to lingering concerns about adverse effects.
Conclusion: COVID-19 vaccination is safe for IBD patients, with side effects similar to or less frequent than those seen in the general population. Clear communication and targeted strategies are needed to alleviate vaccine hesitancy in this vulnerable group.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
